Thus, inhibiting the inflammatory mediators (IL-6, G-CSF) or downstream MEK signaling prevented chemotherapy (DTX)-induced breast cancer dormancy awakening and ameliorated a potentially tumor immunosuppressive microenvironment. This evidence concerns the gene MAP2K7 and breast cancer.